Abstract:Single-arm cohorts/trials are often used in early phase oncology programs to support preliminary clinical activity assessments for investigational products, administered alone or in combination with standard of care (SOC) agents. Benchmarking clinical activity of those combinations against other treatments, including SOC, requires indirect comparisons against external trials, which presents challenges including cross-study differences in trial populations/other factors. To facilitate such nonrandomized comparisons, we developed a comprehensive model-based meta-analysis (MBMA) framework to quantitatively adjust for factors related to efficacy in metastatic non-small cell lung cancer (mNSCLC). Data were derived from 15 published studies assessing key programmed cell death protein-1 (PD-1) inhibitors pembrolizumab (n = 8) and nivolumab (n = 7), representing current SOC in mNSCLC. In the first stage, a mixed-effects logistic regression model for overall response rate (ORR) was developed accounting for effects of various population covariates on ORR. The ORR model results indicated an odds ratio (OR) of 1.02 for squamous versus non-squamous histology and OR of 1.20 for PD-ligand 1 tumor proportion score (TPS) per every 10% increase of TPS level. Next, a nonparametric mixed-effects model for overall survival (OS) was developed with ORR/other clinical covariates as input. Subsequently, MBMA simulations of relevant hypothetical scenarios involving single-arm trial design predicted OS hazard ratios as a function of ORR with matched patient characteristics. Findings from this MBMA and derived parameter estimates can be generally applied by the reader as a framework for interpreting efficacy data from early phase trials to support ORR-based go/no-go decisions and futility rules, illustrated through examples in this report.

A straightforward meta-analysis approach for oncology phase I dose-finding studies

Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors

BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS

Adaptive Dose Modification for Phase I Clinical Trials

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

Application of quantitative pharmacology analysis to support early clinical development of oncology drugs: dose selection

Bayesian dose-regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics

Seamless Phase II/III Design: a Useful Strategy to Reduce the Sample Size for Dose Optimization

U-MET: Utility-Based Dose Optimization Approach for Multiple-Dose Randomized Trial Designs

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

A Dose-Finding Design for Phase I Clinical Trials Based on Bayesian Stochastic Approximation

Phase I–II Clinical Trial Design: a State-of-the-art Paradigm for Dose Finding

A comparison of model-free phase I dose escalation designs for dual-agent combination therapies

Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Incorporating Historical Information to Improve Phase I Clinical Trials

Statistical operating characteristics of current early phase dose finding designs with toxicity and efficacy in oncology

Integration of Efficacy Biomarkers Together with Toxicity Endpoints in Immune-Oncology Dose Finding Studies

Comparative Review of Novel Model‐assisted Designs for Phase I Clinical Trials